Market Overview

The Medicines Co., Bristol-Myers Begin Alliance for Recothrom

Related MDCO
Benzinga's Option Alert Recap From April 11
Benzinga's Option Alert Recap From April 7
Related BMY
D.C. Issues, Including Tax Plan, Steal Some Thunder From Big Earnings Day
12 Stocks To Watch For April 27, 2017
Nasdaq Hits Record High, Pares Gain As Dow, S&P 500 See Red (Investor's Business Daily)

The Medicines Company (NASDAQ: MDCO) announced today that the global license and two-year collaboration for Recothrom(R), a recombinant thrombin approved by the U.S. Food and Drug Administration for use as a topical hemostat to control non-arterial bleeding during surgical procedures, established with Bristol-Myers Squibb Company (NYSE: BMY) has become effective. The agreement was first announced in December 2012. The companies have satisfied all required regulatory and closing conditions.

Posted-In: News


Related Articles (MDCO + BMY)

View Comments and Join the Discussion!